Peptide Therapeutics refer to chemical modification of protein drug and peptide to improve enzymatic strength of the drugs. There has been rapid growth in demand of peptide therapeutics owing to the increasing prevalence of cancer, cardiovascular diseases, Diabetics Mellitus and other life-threatening diseases. For instance, In the United States alone around 1,735,350 new cases of cancer have been recorded in 2018. Rising government initiatives and technological development such as the evolution of hybrid technology which provides easy use of both liquid and solid phase peptide with reduced production time expected to drive the peptide therapeutics market in the long-standing.
Emphasizing on Low Waste Generation during Production of Peptide Therapeutics
Growing Application of Hybrid Technology in Peptide Therapeutics and Increasing Number of Cancer and Diabetics Mellitus Patients
Development of Automation Techniques Associated with Peptide Therapeutics
The Players Covered in the Study are:
Eli Lilly and Company (United States), Pfizer, Inc. (United States), Amgen, Inc. (United States), Takeda Pharmaceutical Company Limited (Japan), Teva Pharmaceuticals Industries Ltd. (Israel), Lonza Inc. (United States), Protagonist Therapeutics, Inc. (United States), Bristol-Myers Squibb (United States), AstraZeneca PLC (United Kingdom), GlaxoSmithKline plc (United Kingdom), Incyte Corporation (United States), AstraZeneca (United Kingdom), Nektar Therapeutics (United States), Next Cure, Inc. (United States) and Dicerna Pharmaceuticals, Inc. (United States)
List of players that can be included in the study on immediate basis are Sanofi (France), Daiichi Sankyo Co. (Japan), Novartis AG (Switzerland) and Novo Nordisk A/S (Denmark).